Upgrade to SI Premium - Free Trial

Rhythm Pharmaceuticals (RYTM) Reiterated at Market Outperform by Citizens

June 3, 2026 4:43 AM
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $155.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments